Survival. (A) PFS for all patients. (B) PFS by achievement of CR as best response. (C) PFS by number of cycles. (D) Overall survival (OS). At the most recent follow-up, transformation was reported in only 1 (1%) patient, after 30 months from initiation of treatment. Secondary cancers (excluding transformation) were diagnosed in 8 (10%) patients after a median of 59 months (range, 3-105). These included melanoma (2), pancreatic adenocarcinoma (1), esophageal adenocarcinoma (1), therapy-related acute myeloid leukemia (1), basal cell carcinoma of the skin (1), smoldering multiple myeloma (1), and renal cell carcinoma (1). Causes of death included secondary cancers in 2 patients (metastatic pancreatic adenocarcinoma and relapsed/refractory acute myeloid leukemia), unrelated comorbid health conditions in 1 patient, and progressive disease in 1 patient. mPFS, median PFS; NR, not reached; PD, progressive disease/death; Resp, response.